0000000000761613

AUTHOR

C. Bucca

showing 6 related works from this author

Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA-ARIA-EPOS-AIRWAYS IC…

2017

Precision medicine (PM) is increasingly recognized as the way forward for optimizing patient care. Introduced in the field of oncology, it is now considered of major interest in other medical domains like allergy and chronic airway diseases, which face an urgent need to improve the level of disease control, enhance patient satisfaction and increase effectiveness of preventive interventions. The combination of personalized care, prediction of treatment success, prevention of disease and patient participation in the elaboration of the treatment plan is expected to substantially improve the therapeutic approach for individuals suffering from chronic disabling conditions. Given the emerging dat…

allergic rhinitis; integrated care pathway; precision medicine; rhinosinusitisAllergyRhinosinusitisDiseaseAllergic rhinitis0302 clinical medicineQUALITY-OF-LIFEMedicineImmunology and Allergy030223 otorhinolaryngologySinusitisNASAL POLYPOSISRhinitisPrecision medicineintegrated care pathway3. Good healthAlgorithmREAL-LIFEIMPACT OUTCOMESARIA and EPOS working groups1107 ImmunologyDISEASESGA(2)LENDisease Progressionallergic rhinitiLife Sciences & BiomedicineENDOSCOPIC SINUS SURGERYAlgorithmsHumanIntegrated care pathwayallergic rhinitis; integrated care pathway; precision medicine; rhinosinusitis; Adult; Algorithms; Chronic Disease; Disease Progression; Humans; Precision Medicine; Rhinitis Allergic; Sinusitis; Young Adult; Immunology and Allergy; ImmunologyAdultmedicine.medical_specialtyprecision medicineImmunologyrhinosinusitiPHENOTYPESVALIDATIONYoung Adult03 medical and health sciencesTherapeutic approachAllergicPatient satisfactionQuality of life (healthcare)HumansSinusitisPatient participationIMMUNOTHERAPYIntensive care medicinerhinosinusitisAsthmaScience & Technologyallergic rhinitis; integrated care pathway; precision medicine; rhinosinusitis; Immunology and Allergy; Immunologyallergic rhinitisbusiness.industrymedicine.diseasePrecision medicineSinusitiRhinitis AllergicSEVERITY030228 respiratory system3121 General medicine internal medicine and other clinical medicineChronic DiseasePhysical therapyASTHMAbusiness
researchProduct

Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry

2020

Abstract Background The clinical and laboratory features of patients enrolled in the Severe Asthma Network in Italy (SANI) registry, a web-based observatory collecting demographic, clinical, functional and inflammatory data of patients with severe asthma were evaluated, with a special emphasis to chronic rhinosinusitis with nasal polyposis (CRSwNP). Methods For each eligible patients the following information has been collected: demographic data, clinical features, asthma control in the previous month according to the GINA (Global INitiative for Asthma) Guidelines and standardized questionnaires, concomitant regular and on demand treatments and inflammatory markers. Results 695 patients wit…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtySevere asthmaDatabases FactualAdministration OralComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioNitric OxideSeverity of Illness IndexComorbiditiesOral corticosteroidAdrenal Cortex HormonesInternal medicineSeverity of illnessOral corticosteroidsmedicinePrevalenceNasal polypsHumansNasal polypsRegistriesSinusitisSinusitisAsthmaAgedRhinitisInternetBronchiectasisbusiness.industryNasal polypSettore MED/09 - MEDICINA INTERNAAtopic dermatitisComorbidities; Nasal polyps; Oral corticosteroids; Severe asthmaMiddle Agedmedicine.diseaseComorbidityAsthmaComorbidities Nasal polyps Oral corticosteroids Severe asthmaItalyConcomitantChronic DiseaseDisease ProgressionFemaleComorbiditiebusiness
researchProduct

Reply to: Kow CS et al. Are severe asthma patients at higher risk of developing severe outcomes from COVID-19?

2021

severe asthma2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Severe asthmaImmunologyComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioCOVID-19 severe asthma COPDNOHumans; SARS-CoV-2; Asthma; COVID-19Internal medicineCorrespondencemedicineCOPDImmunology and AllergyHumansAsthmaCOVIDbusiness.industrySARS-CoV-2COVID-19asthmamedicine.diseaseItalybusiness
researchProduct

Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy

2015

Few data are available on the proportion of asthmatics achieving a good asthma control (according GINA guidelines) and on the level of airway inflammation during omalizumab treatment. The aim of this cross-sectional national observational study was to assess the level of control (according to GINA guidelines) achieved in a group of asthmatics on omalizumab treatment, and to characterize the factors that influence the lack of control. We studied 306 asthmatics under omalizumab treatment for a median of 32 months (range 4-120). The level of control according to GINA was good in 25.2%, partial in 47.1% and poor in 24.5% of patients (data were missing for the remaining 3.2%). Comparison between…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyExacerbationCross-sectional studyOmalizumabOmalizumabComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioExhaled nitric oxide; Exacerbations; Comorbidities; Asthma; Omalizumab; ControlSeverity of Illness IndexComorbiditiesExacerbationsExhaled nitric oxideInternal medicineSeverity of illnessControlMedicineAnti-Asthmatic AgentHumansPharmacology (medical)Anti-Asthmatic AgentsInflammation MediatorAsthmaRespiratory Function TestAgedCross-Sectional Studiebusiness.industryBiochemistry (medical)ExacerbationMiddle Agedmedicine.diseaseComorbidityAsthmaRespiratory Function TestsCross-Sectional StudiesItalyExhaled nitric oxidePhysical therapyObservational studyAsthma; Comorbidities; Control; Exacerbations; Exhaled nitric oxide; Omalizumab; Adult; Aged; Anti-Asthmatic Agents; Asthma; Comorbidity; Cross-Sectional Studies; Female; Humans; Inflammation Mediators; Italy; Male; Middle Aged; Omalizumab; Respiratory Function Tests; Severity of Illness Index; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)FemaleComorbiditieInflammation Mediatorsbusinessmedicine.drugHuman
researchProduct

ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

2016

The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA-disseminated and implemented in over 70 countries globally-is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care p…

PediatricsAIRWAYS ICPs; ARIA; EIP on AHA; ICT; Mobile technology; Rhinitis; Immunology and AllergyIMPACTHay feverRespiratory Medicine and AllergyDiseaseReview[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract0302 clinical medicineQUALITY-OF-LIFEHDE ALERHealth careMedicine and Health SciencesPERSISTENT ALLERGIC RHINITISMedicineImmunology and Allergy030212 general & internal medicine[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/AllergologyAIRWAYS ICPComputingMilieux_MISCELLANEOUSRhinitiAIRWAYS ICPs; ARIA; EIP on AHA; ICT; Mobile technology; RhinitisLungmedicin och allergiRhinitisPublic Health Global Health Social Medicine and Epidemiology3. Good healthREAL-LIFEAIRWAYS ICPsARIA; Rhinitis; ICT; EIP on AHA; Mobile technology; AIRWAYS ICPsHay feverCLINICAL-PRACTICE GUIDELINESHEALTHPulmonary and Respiratory Medicinemedicine.medical_specialtyEIP on AHAEUROPEAN INNOVATION PARTNERSHIPImmunologySocio-culturaleClinical decision support systemICT; EIP on AHAPredictive medicine03 medical and health sciencesQuality of life (healthcare)Mobile technologyJournal ArticleMobile technologyAsmaAsthmaScience & TechnologyARIAbusiness.industryAIRWAYS ICPs; ARIA; EIP on AHA; ICT; Mobile technology; Rhinitis;Settore MED/09 - MEDICINA INTERNAAIRWAYS-ICPSCorrectionmedicine.disease2008 UPDATEFebre del fencAsthmaFolkhälsovetenskap global hälsa socialmedicin och epidemiologi030228 respiratory systemFamily medicineICTVISUAL ANALOG SCALEbusiness
researchProduct

Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

2019

AIMS: Mobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA-LR of Montpellier, France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle, whatever their gender or socio-economic status, in order to reduce health and social inequities incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change the management strategy in chronic diseases. METHODS: MASK implements ICT technologies for individualized and predictive medicine to develop novel care pathways by a multi-disciplinary group centred around the patients. STAKEHOLDERS: Incl…

SENTINEL NETWORKAllergyRespiratory Medicine and AllergyReviewWORLD-HEALTH-ORGANIZATIONDiseaseRhinitis.App; Asthma; Care pathways; DG Santé; MASK; mHealth; Rhinitis0302 clinical medicineQUALITY-OF-LIFEPRECISION MEDICINEDG SantéHealth careMedicine and Health SciencesGRADING QUALITYImmunology and AllergyMedicinemHealthRinitisLungmedicin och allergiRhinitis0303 health sciencesThe MASK study groupPublic sectorApp ; Asthma ; Care pathways ; MASK ; mHealth ; Rhinitis ; DG SanteMOBILE TECHNOLOGY3. Good healthALLERGIC RHINITISCHRONIC RESPIRATORY-DISEASESRinitemHealthCare pathwaysEUROPEAN SYMPOSIUMCLINICAL-PRACTICE GUIDELINESLife Sciences & BiomedicinePulmonary and Respiratory Medicinemedicine.medical_specialtyMASKImmunologySettore MED/10 - Malattie Dell'Apparato RespiratorioPredictive medicine03 medical and health sciencesQuality of life (healthcare)App -MASKAsma030304 developmental biologyAsthmaARIAScience & TechnologyCare pathwaybusiness.industryChange managementCorrectionDG SanteRC581-607medicine.diseaseAsthma030228 respiratory systemApp; Asthma; Care pathways; DG Santé; MASK; mHealth; Rhinitis; Immunology and Allergy; Immunology; Pulmonary and Respiratory MedicineFamily medicineImmunologic diseases. AllergybusinessApp[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct